Ipsen presents long-term IQIRVO data at liver disease conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall St rises as softer jobs data calms rate-hike fears
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil falls to four-month low as US, Iran conclude talks in Doha
- Stocks gain, dollar weakens after jobs report softens rate hike bets
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Meta Platforms stock surges 8% on cloud business plans
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Wall Street ends choppy session lower as tech shares drop
Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue
November 7, 2025 8:42 AM ESTInterim data from the IQIRVO® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in improvement of fatigue and pruritus symptoms, with a well-characterized safety profile over more than three years of treatment Additional new data from the ELATIVE trial highlights the potential for IQIRVO, a PPAR / agonist, to beneficially impact fatigue-associated pathways linked to mitochondrialfunction Â
Paris, France  7 November, 2025 Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new Primary Biliary Cholangitis (PBC) data with IQIRVO® from the... More
